title: The impact of statins on FGF-2-stimulated human umbilical vein endothelial cells.
abstract: OBJECTIVE
  To determine the effects of different types of statins on proliferative and migrative behaviors of basic fibroblastic growth factor (FGF)-2-stimulated endothelial cells.
  
  
  METHODS
  Human umbilical vein endothelial cells (HUVECs) were isolated and cultured. Groups were arranged in order to observe the impact of each individual substance alone, or under stimulation with statin on FGF-2-stimulated endothelial cells. Endothelial cells were stimulated with human growth factor (HGF), statins, methyl-β-cyclodextrin (β-MCD), and either farnesyl pyrophosphate (FPP) ammonium salt, or geranylgeranyl-pyrophosphate (GGPP), respectively. Cell proliferation analyses were performed 48 hours after stimulation and gaps between migration borders were used in migration analyses.
  
  
  RESULTS
  The statins showed significant antiproliferative and anti-migrative effects and inhibited the proliferative behavior of FGF-2. However, endothelial cell proliferation and migration were significantly increased after mevalonate co-incubation. Experiments with β-MCD indicated that the destruction of lipid rafts had a negative impact on the action of FGF-2. Stimulation of statin-incubated cells with FPP had no additional effect on proliferation or migration. Notably, although FGF-2 exerted a pro-migrative effect, the effect was not shown in the FPP + FGF-2 group. The anti-migrative actions of statins along with disruption of membrane integrity were reversed by the addition of GGPP.
  
  
  CONCLUSIONS
  The angiogenic effect of FGF-2 is suppressed through inhibition of the intracellular cholesterol biosynthesis via statins. Inhibitory effects of statins on FGF-2-stimulated HUVECs were observed to result from both the inhibition of isoprenylation and the destruction of lipid rafts on the cell membrane.
authors.affiliation: Department of Internal Medicine and Angiology, Wuppertal Research and Medical Center, Wuppertal, Germany. burgazlk@uni-koeln.de.
authors.forename: Kamil Mehmet
authors.initials: KM
authors.lastname: Burgazli
authors.forename: Mark Andre
authors.initials: MA
authors.lastname: Behrendt
authors.forename: Meric
authors.initials: M
authors.lastname: Mericliler
authors.forename: Ritvan
authors.initials: R
authors.lastname: Chasan
authors.forename: Mariana
authors.initials: M
authors.lastname: Parahuleva
authors.forename: Ali
authors.initials: A
authors.lastname: Erdogan
mesh_terms: D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002784:Cholesterol / Q000096:biosynthesis; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D021962:Membrane Microdomains / Q000187:drug effects / Q000378:metabolism; D008798:Mevalonic Acid / Q000494:pharmacology; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D014471:Umbilical Veins; D047392:beta-Cyclodextrins / Q000494:pharmacology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D036341:Intercellular Signaling Peptides and Proteins; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D016222:Fibroblast Growth Factor 2; D002784:Cholesterol; D008798:Mevalonic Acid